Results 61 to 70 of about 112,829,295 (166)

Is the innate bio-protection power against human virus the same between males and females? A conclusion based on blood donor data of HTLV-I infection [PDF]

open access: yes, 2008
Human T-cell leukemia virus type I (HTLV-I) is a retrovirus that causes adult T-cell leukemia. The male-to-female transmission is stronger than the reverse, so the carrier proportion of women is greater than that of men.
Minoru Tabata   +3 more
core  

Frequency of positive HTLV-1/HTLV-2 tests in relatives of HTLV carriers from Belém.

open access: yes, 2013
Frequency of positive HTLV-1/HTLV-2 tests in relatives of HTLV carriers from Belém.
Antonio Carlos Rosário Vallinoto (421928)   +11 more
core   +1 more source

The reasons to include the serology of human T-lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2) in the clinical follow-up of patients with viral hepatitis B and C in Brazil.

open access: yesPLoS Neglected Tropical Diseases, 2020
BACKGROUND:The WHO established targets for 2030 to globally reduce new viral hepatitis B and C infections by 90% and deaths by 65% and recommends searching for coinfections that increase the progression of chronic liver infections towards cirrhosis and ...
Karoline Rodrigues Campos   +5 more
doaj   +1 more source

Prevalence and risk factor analysis for HIV/HTLV 1/2 coinfection in Paraíba state, Brazil

open access: yesJournal of Infection in Developing Countries, 2021
Introduction: Human T-lymphotropic virus (HTLV) 1 and 2 infections can lead to neurological diseases, mainly in HIV/HTLV 1 coinfected. Furthermore, HTLV 1 infection in HIV/AIDS patients has also been associated with AIDS progression.
Marcela Santos de Souza   +6 more
doaj   +1 more source

Distinct Clinical Features of Multiple Myeloma With t(11;14): A Post Hoc Analysis of JSH‐MM‐15 Study

open access: yesCancer Science, EarlyView.
t(11;14)‐positive MM is a clinically distinct subgroup characterized by intermediate prognostic risk, modest response depth, and treatment‐dependent outcomes. ABSTRACT t(11;14) (q13;q32) occurs in approximately 15%–25% of multiple myeloma (MM) cases and has traditionally been regarded as a standard cytogenetic risk factor.
Taku Tsukamoto   +24 more
wiley   +1 more source

Human T-lymphotropic viruses types 1 and 2 in the 21st century (A systematic review)

open access: yesЖурнал инфектологии
Human T-lymphotropic viruses types 1 and 2 (HTLV-1/2) (family Retroviridae, genus Deltaretrovirus), are due to their genomic organization capable of long persistence and latency in the human body.
P. V. Apanovich   +2 more
doaj   +1 more source

Strengths, Weaknesses, Opportunities and Threats (SWOT) Analysis of the Implementation of Public Health Policies on HTLV-1 in Brazil

open access: yesFrontiers in Medicine, 2022
Human T lymphotropic virus 1 (HTLV-1) is a public health issue for most countries and imposes important consequences on patients' health and socioeconomic status. Brazil is one of the global leaders of the public health response to these viruses.
Angelica Espinosa Miranda   +7 more
doaj   +1 more source

Innate Immune Activation Is a Strong Suppressor of CCL22 and Impedes Regulatory T Cell–Dendritic Cell Interaction

open access: yesImmunology, EarlyView.
During homeostasis, CCL22 is secreted by dendritic cells (DC), which mediate contacts between regulatory T cells (Treg) and DC to maintain immune balance. Activation of innate immunity via microbes or pattern recognition receptor (PRR) agonists induces the secretion of several soluble factors (e.g., type I and II interferons, IL‐10), which mediate ...
Ignazio Piseddu   +24 more
wiley   +1 more source

Immunological characteristics of Spanish IDUs infected with HTLV-2 and HIV-1 [PDF]

open access: yesRetrovirology, 2011
Background HTLV-2 infection has been detected in injecting drug users (IDUs) in Spain, who often are coinfected with HCV and HIV-1. It has been reported that HCV infection increases the immune activation of HIV-1-infected patients. Our objective was to analyze how HTLV-2 infection affects T-cell activation and other immunological parameters such as ...
Moreno Santiago   +6 more
openaire   +2 more sources

Harnessing the Therapeutic Potential of Cell Secretomes and Extracellular Vesicles for Craniofacial Regenerative Applications

open access: yesJournal of Periodontal Research, EarlyView.
The scoping review summarizes the current preclinical and clinical evidence for the use of “cell‐free” therapies in craniofacial (periodontal, bone and soft‐tissue) regeneration. It also aims to highlight key challenges and strategies towards the clinical translation of these therapies.
Siddharth Shanbhag   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy